Gregory Mishkel, MD

Pharmaceutical, device, and biotechnology companies frequently collaborate with research scientists and physicians to help advance scientific knowledge and improve patient care. These relationships can support scientific breakthroughs and help establish the effectiveness and safety of promising new therapies.

To ensure objectivity in clinical research and patient care, Endeavor Health maintains integrity policies requiring researchers and clinicians — whether in full-time, part-time and unpaid or voluntary roles — to disclose compensated and uncompensated relationships with external industry organizations.

Patients are encouraged to discuss these relationships with their physician as well as to inquire as to how these relationships are overseen by Endeavor Health. Learn more about our Conflict of Interest and Commitment Policy.

Additionally, patients can visit the Centers for Medicare & Medicaid Services (CMS) Open Payments website, a national disclosure program that promotes a more transparent and accountable healthcare system. It houses a publicly accessible database of payments that reporting entities — including pharmaceutical, device, and biotechnology companies — make to covered recipients such as physicians and hospitals.

CMS is required by law to publish this data annually on or before June 30 for the previous reporting year. The data is published annually, so it may not reflect the most recent reporting period. If you have questions about the information, talk with your physician.